Montara Therapeutics, Inc. — Form D
Montara Therapeutics, Inc. of SAN FRANCISCO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2024-01-19. The offering totals $17.0M, of which $8.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-01-19
- Form: D
- Accession: 0002008775-24-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $17.0M
- Amount sold: $8.0M
- Remaining: $9.0M
- Investors: 5
- Date of first sale: 2024-01-05
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-502979
Issuer
- Name: Montara Therapeutics, Inc.
- CIK: 0002008775
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2022
- Address: 135 MISSISSIPPI STREET, SAN FRANCISCO, CA, 94107
- Phone: 310-463-6172
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Max Lebovitz | Executive Officer | San Francisco, CA |
| Seth Stratton | Director | San Francisco, CA |
| Troy Wilson | Director | San Francisco, CA |
| Zachary Hill | Executive Officer | San Francisco, CA |
| Rishi Rakhit | Executive Officer | San Francisco, CA |
| Randall Chin | Executive Officer | San Francisco, CA |
| Dirk Langdorf | Director | San Francisco, CA |
| Nicholas Hertz | Director | San Francisco, CA |
| Nicholas Hertz | Executive Officer | San Francisco, CA |
| Nicholas Hertz | Promoter | San Francisco, CA |
Other filings by this issuer (1)
More